Tri-specific antibodies for HIV therapy

Patent metadata

Field	Value
Publication number	US-10654943-B2
Application number	US-201615579280-A
Country	US
Kind code	B2
Filing date	Jun 2, 2016
Priority date	Jun 2, 2015
Publication date	May 19, 2020
Grant date	May 19, 2020

Abstract

Provided are tri-specific fusion antibodies created to target multiple epitopes of the Human Immunodeficiency Virus (HIV). The fusion antibodies provide improved potency and breadth against HIV as compared to monospecific and bispecific antibodies, and additionally provide a high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

First claim

What is claimed is:

1. A tri-specific antibody, comprising first, second and third antigen-binding sites which are capable of binding with specificity to first, second and third distinct epitopes that are comprised by a Human Immunodeficiency Virus (HIV), wherein the first, second and third antigen-binding sites comprise antigen binding sites of PGT128/3BNC117-PGDM1400 antibodies, and wherein the antigen binding site of the PGDM1400 antibody is at the C-terminus of the tri-specific antibody, and wherein the antigen binding site of the PGDM1400 antibody is optionally linked to the C-terminus of the heavy chain of the tri-specific antibody by a GS linker.

2. The tri-specific antibody of claim 1 , wherein said anti-HIV antibody is humanized.

3. A method of treating a subject infected with Human Immunodeficiency Virus (HIV) comprising administering to the subject a therapeutically effective amount of a tri-specific antibody of claim 1 .

4. A method of inhibiting Human Immunodeficiency Virus (HIV)-positive pregnant subject from transmitting the HIV to the fetus or newborn, comprising administering to the subject and/or the newborn a therapeutically effective amount of the tri-specific antibody according to claim 1 .

5. A pharmaceutical composition comprising a tri-specific antibody of claim 1 .

6. The method of claim 3 , wherein said anti-HIV antibody is humanized.

7. The pharmaceutical composition of claim 5 , wherein anti-HIV antibody is humanized.

8. The method of claim 4 , wherein anti-HIV antibody is humanized.

Assignees

• Univ Rockefeller

Inventors

• Ho David
• Yu Jian
• Yao Xin
• Huang Yaoxing

Classifications

• C07K2317/31

  multispecific · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/90

  characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title